Abstract:Recently, molecular generation models based on deep learning have attracted significant attention in drug discovery. However, most existing molecular generation models have serious limitations in the context of drug design wherein they do not sufficiently consider the effect of the three-dimensional (3D) structure of the target protein in the generation process. In this study, we developed a new deep learning-based molecular generator, SBMolGen, that integrates a recurrent neural network, a Monte Carlo tree search, and docking simulations. The results of an evaluation using four target proteins (two kinases and two G protein-coupled receptors) showed that the generated molecules had a better binding affinity score (docking score) than the known active compounds, and the generated molecules possessed a broader chemical space distribution. SBMolGen not only generates novel binding active molecules but also presents 3D docking poses with target proteins, which will be useful in subsequent drug design. The code is available at <a class="extLink" href="https://github.com/clinfo/SBMolGen">https://github.com/clinfo/SBMolGen</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.1c00679?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.1c00679</a>.Number of generated molecules, example of generated molecules for target EGFR at C = 1.0, example of generated molecules for target AA2AR at C = 1.0, example of generated molecules for target ADRB2 at C = 1.0; distribution of the similarity score of the generated molecules and distribution of the scaffold similarity score of the generated molecules; distribution of the SA scores of the generated molecules; distributions of the QED scores of the generated molecules; plots of IFIE<sub>sum</sub> against experimentally determined Δ<i>G</i> for (A) nine CDK2 inhibitors and (B) generated molecules; distribution of the docking scores of the generated molecules against DDR1; chemical structures of nine CDK2 inhibitors and their properties (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.1c00679/suppl_file/ci1c00679_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

De Novo Design of Hsp70 Inhibitors with Objective Reinforced Generative Adversarial Networks (ORGAN) and Docking

Change in appearance of the optic disc associated with lowering of intraocular pressure.

Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets

Target-specific design of drug-like PPI inhibitors via hot-spot-guided generative deep learning

Machine Learning Aided De Novo Design Identifies Novel Benzimidazolone Based Inhibitor‐Modulators for Heat Shock Protein 90 (HSP90)

Structure-Based de Novo Molecular Generator Combined with Artificial Intelligence and Docking Simulations

We Should at Least Be Able to Design Molecules That Dock Well

Generative adversarial network (GAN) model-based design of potent SARS-CoV-2 Mpro inhibitors using the electron density of ligands and 3D binding pockets: insights from molecular docking, dynamics simulation, and MM-GBSA analysis

Improving drug discovery with a hybrid deep generative model using reinforcement learning trained on a Bayesian docking approximation

DOCKSTRING: Easy Molecular Docking Yields Better Benchmarks for Ligand Design

A Simple Way to Incorporate Target Structural Information in Molecular Generative Models

De novo generation of dual-target ligands using adversarial training and reinforcement learning

De novo generation of multi-target compounds using deep generative chemistry

DOCK 6: Impact of new features and current docking performance

Efficient Exploration of Chemical Space with Docking and Deep Learning

Deep Generation Model Guided by the Docking Score for Active Molecular Design

Decipher Fundamental Atomic Interactions to Unify Generative Molecular Docking and Design

Parallel multi-swarm cooperative particle swarm optimization for protein–ligand docking and virtual screening

Prospective de novo drug design with deep interactome learning

Structure-based <i>de novo</i> drug design using 3D deep generative models

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design